Junshi Biosciences Announces 2021 Interim Financial Results and Provides Corporate Updates

NEXT STORY
Operational Highlights and Financial Results for the Year Ended June 30, 2021
PREV STORY
Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication

Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough ...

author_avatar
NASDAQ Market News

KLOX Technologies reports on its interim results from its ongoing clinical studies on LumiHeal™ for the treatment of chronic wounds and postsurgical scarring

LAVAL, Quebec, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Today, clinical interim results on KLOX ...

author_avatar
NASDAQ Market News

Global Point-of-Care Diagnostics, Health & Biosensors Conference 2019: POC Testing Landscape, Novel Technologies to Regulatory Approval (San Diego, CA, United States – October 7-9, 2019)

author_avatar
NASDAQ Market News